Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2015

Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2015

Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2015’, provides an overview of the Respiratory Syncytial Virus (RSV) Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Respiratory Syncytial Virus (RSV) Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Respiratory Syncytial Virus (RSV) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Respiratory Syncytial Virus (RSV) Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Respiratory Syncytial Virus (RSV) Infections Overview 11
Therapeutics Development 12
Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Overview 12
Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis 13
Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Development by Companies 14
Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Investigation by Universities/Institutes 19
Respiratory Syncytial Virus (RSV) Infections - Pipeline Products Glance 21
Clinical Stage Products 21
Early Stage Products 22
Respiratory Syncytial Virus (RSV) Infections - Products under Development by Companies 23
Respiratory Syncytial Virus (RSV) Infections - Products under Investigation by Universities/Institutes 28
Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development 29
3-V Biosciences, Inc. 29
Ablynx NV 30
ADMA Biologics, Inc. 31
Agilvax, Inc. 32
AlphaVax, Inc. 33
AmVac AG 34
Aridis Pharmaceuticals LLC 35
Artificial Cell Technologies, Inc. 36
Astellas Pharma Inc. 37
AstraZeneca Plc 38
Bavarian Nordic A/S 39
Biota Pharmaceuticals, Inc. 40
Celltrion, Inc. 41
Codagenix, Inc. 42
Crucell N.V. 43
CureVac GmbH 44
Emergent BioSolutions Inc. 45
Evec, Inc. 46
F. Hoffmann-La Roche Ltd. 47
GenVec, Inc. 48
Gilead Sciences, Inc. 49
GlaxoSmithKline Plc 50
Humabs BioMed SA 51
iBio, Inc. 52
Immunovaccine, Inc. 53
Johnson & Johnson 54
Kineta, Inc. 55
MedImmune, LLC 56
Medivir AB 57
Merck & Co., Inc. 58
Microbiotix, Inc. 59
MSM Protein Technologies, Inc. 60
Mucosis B.V. 61
NanoBio Corporation 62
Navigen Pharmaceuticals, Inc. 63
Novavax, Inc. 64
Panacea Biotec Limited 65
Pulmocide Ltd 66
Regeneron Pharmaceuticals, Inc. 67
REPLICor Inc. 68
Romark Laboratories, L.C. 69
Sirnaomics, Inc. 70
Spring Bank Pharmaceuticals, Inc. 71
Symphogen A/S 72
Takeda Pharmaceutical Company Limited 73
TechnoVax, Inc. 74
Vaxart, Inc. 75
Virometix AG 76
Respiratory Syncytial Virus (RSV) Infections - Therapeutics Assessment 77
Assessment by Monotherapy Products 77
Assessment by Combination Products 78
Assessment by Target 79
Assessment by Mechanism of Action 81
Assessment by Route of Administration 83
Assessment by Molecule Type 85
Drug Profiles 87
AK-0529 - Drug Profile 87
ALS-8112 - Drug Profile 88
ALS-8176 - Drug Profile 89
ALX-0171 - Drug Profile 90
AMV-601 - Drug Profile 92
AMV-602 - Drug Profile 93
AMV-603 - Drug Profile 94
AMV-611 - Drug Profile 95
AR-201 - Drug Profile 96
AZ-27 - Drug Profile 97
BTAC-585 - Drug Profile 98
danirixin - Drug Profile 99
DPX-RSV - Drug Profile 101
Drugs to Inhibit STAT for RSV Infection - Drug Profile 102
EV-046120 - Drug Profile 103
EV-046135 - Drug Profile 104
GBV-006 - Drug Profile 105
GSK-3003891A - Drug Profile 106
GV-2311 - Drug Profile 107
human parainfluenza virus [type 1] + respiratory syncytial virus vaccine - Drug Profile 108
IKT-041 - Drug Profile 109
influenza + RSV vaccine - Drug Profile 110
JNJ-53718678 - Drug Profile 111
JNJ-61187191-AAA - Drug Profile 112
MBX-300 - Drug Profile 113
MEDI-7510 - Drug Profile 115
MEDI-8897 - Drug Profile 117
Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections - Drug Profile 118
Monoclonal Antibody for Respiratory Syncytial Virus - Drug Profile 119
Monoclonal Antibody for RSV Infections - Drug Profile 120
Monoclonal Antibody to Inhibit RSV-G and RSV-F for RSV Infections - Drug Profile 121
MPE-8 - Drug Profile 122
MSM-605 - Drug Profile 123
MVA-BN-RSV - Drug Profile 124
MVA-RSV - Drug Profile 125
Oligonucleotide for Respiratory Syncytial Viral Infections - Drug Profile 126
palivizumab biosimilar - Drug Profile 127
palivizumab biosimilar - Drug Profile 128
palivizumab biosimilar - Drug Profile 129
pertussis [strain BPZE1] vaccine - Drug Profile 130
presatovir - Drug Profile 131
Recombinant Protein for RSV Infections - Drug Profile 132
REGN-2222 - Drug Profile 133
REP-9 - Drug Profile 134
respiratory syncytial virus like particle vaccine - Drug Profile 135
respiratory syncytial virus like particle vaccine - Drug Profile 136
respiratory syncytial virus vaccine - Drug Profile 137
respiratory syncytial virus vaccine - Drug Profile 139
respiratory syncytial virus vaccine - Drug Profile 140
respiratory syncytial virus vaccine - Drug Profile 143
respiratory syncytial virus vaccine - Drug Profile 144
respiratory syncytial virus vaccine - Drug Profile 145
respiratory syncytial virus vaccine - Drug Profile 147
respiratory syncytial virus vaccine - Drug Profile 148
respiratory syncytial virus vaccine - Drug Profile 149
respiratory syncytial virus vaccine - Drug Profile 150
respiratory syncytial virus vaccine - Drug Profile 151
respiratory syncytial virus vaccine - Drug Profile 153
respiratory syncytial virus vaccine - Drug Profile 154
respiratory syncytial virus vaccine - Drug Profile 155
respiratory syncytial virus vaccine - Drug Profile 156
respiratory syncytial virus vaccine - Drug Profile 157
respiratory syncytial virus vaccine - Drug Profile 158
respiratory syncytial virus vaccine 1 - Drug Profile 159
respiratory syncytial virus vaccine 2 - Drug Profile 160
respiratory syncytical virus + influenza vaccine - Drug Profile 161
RI-002 - Drug Profile 162
RNAi Oligonucleotide for Respiratory Syncytial Virus Infection - Drug Profile 164
RNAi Oligonucleotides for RSV and Viral Respiratory Tract Infections - Drug Profile 165
rOAS - Drug Profile 166
RSV [strain 98-25147-X] vaccine - Drug Profile 167
RSV vaccine - Drug Profile 168
RSV vaccine - Drug Profile 169
RSV vaccine - Drug Profile 170
RSV virus like particle vaccine - Drug Profile 171
RSV-001 - Drug Profile 172
RV-521 - Drug Profile 173
SB-9200 - Drug Profile 174
Small Molecule to Agonize IRF-3 for Viral Infections - Drug Profile 176
Small Molecules for Respiratory Syncitial Virus and Herpes Simplex Virus Infections - Drug Profile 177
Small Molecules for Respiratory Syncytial Virus Infections - Drug Profile 178
Small Molecules for RSV and Influenza A Infections - Drug Profile 179
Small Molecules for RSV Infections - Drug Profile 180
Small Molecules to Inhibit Fatty Acid Synthase for Viral Infections - Drug Profile 181
Small Molecules to Inhibit Respiratory Syncytial Virus Fusion Protein for RSV Infections - Drug Profile 182
Small Molecules to Inhibit Viral RNA Polymerase for RSV Infections - Drug Profile 183
STP-902 - Drug Profile 184
Sym-003 - Drug Profile 185
Synthetic Peptides to Inhibit RSV-F Protein for RSV Infection - Drug Profile 186
TVX-004IP - Drug Profile 187
Respiratory Syncytial Virus (RSV) Infections - Recent Pipeline Updates 188
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects 208
Respiratory Syncytial Virus (RSV) Infections - Discontinued Products 211
Respiratory Syncytial Virus (RSV) Infections - Product Development Milestones 212
Featured News & Press Releases 212
Appendix 220
Methodology 220
Coverage 220
Secondary Research 220
Primary Research 220
Expert Panel Validation 220
Contact Us 220
Disclaimer 221

List of Tables
Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H1 2015 18
Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis, H1 2015 19
Number of Products under Development by Companies, H1 2015 21
Number of Products under Development by Companies, H1 2015 (Contd..1) 22
Number of Products under Development by Companies, H1 2015 (Contd..2) 23
Number of Products under Development by Companies, H1 2015 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H1 2015 25
Comparative Analysis by Clinical Stage Development, H1 2015 27
Comparative Analysis by Early Stage Development, H1 2015 28
Products under Development by Companies, H1 2015 29
Products under Development by Companies, H1 2015 (Contd..1) 30
Products under Development by Companies, H1 2015 (Contd..2) 31
Products under Development by Companies, H1 2015 (Contd..3) 32
Products under Development by Companies, H1 2015 (Contd..4) 33
Products under Investigation by Universities/Institutes, H1 2015 34
Respiratory Syncytial Virus (RSV) Infections - Pipeline by 3-V Biosciences, Inc., H1 2015 35
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Ablynx NV, H1 2015 36
Respiratory Syncytial Virus (RSV) Infections - Pipeline by ADMA Biologics, Inc., H1 2015 37
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Agilvax, Inc., H1 2015 38
Respiratory Syncytial Virus (RSV) Infections - Pipeline by AlphaVax, Inc., H1 2015 39
Respiratory Syncytial Virus (RSV) Infections - Pipeline by AmVac AG, H1 2015 40
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Aridis Pharmaceuticals LLC, H1 2015 41
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Artificial Cell Technologies, Inc., H1 2015 42
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Astellas Pharma Inc., H1 2015 43
Respiratory Syncytial Virus (RSV) Infections - Pipeline by AstraZeneca Plc, H1 2015 44
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Bavarian Nordic A/S, H1 2015 45
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Biota Pharmaceuticals, Inc., H1 2015 46
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Celltrion, Inc., H1 2015 47
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Codagenix, Inc., H1 2015 48
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Crucell N.V., H1 2015 49
Respiratory Syncytial Virus (RSV) Infections - Pipeline by CureVac GmbH, H1 2015 50
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Emergent BioSolutions Inc., H1 2015 51
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Evec, Inc., H1 2015 52
Respiratory Syncytial Virus (RSV) Infections - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 53
Respiratory Syncytial Virus (RSV) Infections - Pipeline by GenVec, Inc., H1 2015 54
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Gilead Sciences, Inc., H1 2015 55
Respiratory Syncytial Virus (RSV) Infections - Pipeline by GlaxoSmithKline Plc, H1 2015 56
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Humabs BioMed SA, H1 2015 57
Respiratory Syncytial Virus (RSV) Infections - Pipeline by iBio, Inc., H1 2015 58
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Immunovaccine, Inc., H1 2015 59
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Johnson & Johnson, H1 2015 60
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Kineta, Inc., H1 2015 61
Respiratory Syncytial Virus (RSV) Infections - Pipeline by MedImmune, LLC, H1 2015 62
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Medivir AB, H1 2015 63
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Merck & Co., Inc., H1 2015 64
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Microbiotix, Inc., H1 2015 65
Respiratory Syncytial Virus (RSV) Infections - Pipeline by MSM Protein Technologies, Inc., H1 2015 66
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Mucosis B.V., H1 2015 67
Respiratory Syncytial Virus (RSV) Infections - Pipeline by NanoBio Corporation, H1 2015 68
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Navigen Pharmaceuticals, Inc., H1 2015 69
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Novavax, Inc., H1 2015 70
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Panacea Biotec Limited, H1 2015 71
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Pulmocide Ltd, H1 2015 72
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 73
Respiratory Syncytial Virus (RSV) Infections - Pipeline by REPLICor Inc., H1 2015 74
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Romark Laboratories, L.C., H1 2015 75
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Sirnaomics, Inc., H1 2015 76
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2015 77
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Symphogen A/S, H1 2015 78
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 79
Respiratory Syncytial Virus (RSV) Infections - Pipeline by TechnoVax, Inc., H1 2015 80
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Vaxart, Inc., H1 2015 81
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Virometix AG, H1 2015 82
Assessment by Monotherapy Products, H1 2015 83
Assessment by Combination Products, H1 2015 84
Number of Products by Stage and Target, H1 2015 86
Number of Products by Stage and Mechanism of Action, H1 2015 88
Number of Products by Stage and Route of Administration, H1 2015 90
Number of Products by Stage and Molecule Type, H1 2015 92
Respiratory Syncytial Virus (RSV) Infections Therapeutics - Recent Pipeline Updates, H1 2015 194
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H1 2015 214
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..1), H1 2015 215
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..2), H1 2015 216
Respiratory Syncytial Virus (RSV) Infections - Discontinued Products, H1 2015 217

List of Figures
Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H1 2015 18
Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis, H1 2015 19
Number of Products under Development by Companies, H1 2015 20
Number of Products under Investigation by Universities/Institutes, H1 2015 25
Comparative Analysis by Clinical Stage Development, H1 2015 27
Comparative Analysis by Early Stage Products, H1 2015 28
Assessment by Monotherapy Products, H1 2015 83
Number of Products by Top 10 Targets, H1 2015 85
Number of Products by Stage and Top 10 Targets, H1 2015 85
Number of Products by Top 10 Mechanism of Actions, H1 2015 87
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 87
Number of Products by Top 10 Routes of Administration, H1 2015 89
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 89
Number of Products by Top 10 Molecule Types, H1 2015 91
Number of Products by Stage and Top 10 Molecule Types, H1 2015 91

Looking for something else?